Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

682
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
682
Anthelminthic Agents01:15

Anthelminthic Agents

55
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
55
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

64
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
64
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial barrier disorder in hereditary angioedema: molecular mechanisms and therapeutic implications.

Frontiers in immunology·2026
Same author

Metabolic profiling reveals circadian rhythms and lifestyle-associated changes.

Science China. Life sciences·2026
Same author

Selective Pyroptosis in NF1-Deficient Cells through PKCδ Agonism.

bioRxiv : the preprint server for biology·2026
Same author

Identification of Potential Plasma Biomarkers of Abdominal Aortic Aneurysm Using a Metabolomics Approach.

Current molecular medicine·2026
Same author

Risk-updating nomogram for refractory systemic JIA in children: multicentre development and external validation.

Rheumatology (Oxford, England)·2026
Same author

Valosin-Containing Protein Contributes to Plexiform Neurofibroma Formation and Represents a Novel Therapeutic Target.

Cells·2026
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

10.2K

Methotrexate and Pralatrexate.

Gary S Wood1, Jianqiang Wu1

  • 1Department of Dermatology, University of Wisconsin and VA Medical Center, 7th Floor, One South Park, Madison, WI 53715, USA.

Dermatologic Clinics
|October 5, 2015
PubMed
Summary
This summary is machine-generated.

This review covers methotrexate and pralatrexate for cutaneous T-cell lymphomas, highlighting their roles as epigenetic regulators beyond antiproliferative effects. Combination therapy shows promise for improved treatment outcomes.

Keywords:
ApoptosisDihydrofolate reductaseFolateFolic acidMethotrexatePralatrexatePurine synthesisS phase

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K

Related Experiment Videos

Last Updated: Apr 1, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

10.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and Sézary syndrome, are challenging hematologic malignancies.
  • Methotrexate and pralatrexate are folate antagonists used in CTCL treatment.
  • Their mechanism extends beyond cell cycle inhibition to epigenetic regulation via DNA methylation inhibition.

Purpose of the Study:

  • To review the efficacy and mechanisms of methotrexate and pralatrexate in treating CTCL.
  • To explore their roles as epigenetic regulators in CTCL.
  • To propose novel therapeutic strategies involving folate antagonists.

Main Methods:

  • Literature review of methotrexate and pralatrexate in CTCL treatment.
  • Analysis of their mechanisms of action, including antiproliferative and epigenetic effects.
  • Inclusion of recent mathematical modeling data on combination therapy.

Main Results:

  • Folate antagonists like methotrexate and pralatrexate exhibit antiproliferative and DNA methylation inhibitory effects.
  • These compounds show potential as epigenetic regulators in CTCL.
  • Mathematical modeling suggests combination therapy may offer superior outcomes.

Conclusions:

  • Methotrexate and pralatrexate have established roles in CTCL treatment, with emerging understanding of their epigenetic functions.
  • Their dual action as antiproliferative and epigenetic agents warrants further investigation.
  • Novel combination therapies involving folate antagonists represent a promising future direction for CTCL management.